Navigation Links
GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission
Date:10/3/2011

SEATTLE, Oct. 3, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals Hamilton has donated a broad range of instrumentation and equipment that will assist IDRI as it designs and validates solutions to reduce the burden of disease in the developing world. IDRI will apply the gift as it prepares for clinical trials in the areas of tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza.

"We at IDRI view this generous gift by our friends at GSK as a demonstration of confidence that the products IDRI is researching today will soon be making a difference for people worldwide," said H. Stewart Parker, IDRI's Chief Executive Officer.  "GSK's generous donation will enable new health technologies to be deployed for a number of diseases that particularly affect those in low resource settings."

"GSK has seen IDRI's talented scientists develop world-class technologies that have entered into numerous successful clinical trials," said Pamela Sager, Business Support Manager at GSK.  "We believe that the equipment we are giving to IDRI will not only further the world's scientific understanding of infectious diseases, but that this gift will also advance IDRI's global health mission."

GSK acquired the equipment when the company purchased the former Corixa site in Seattle in 2005.

About IDRI
IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.

For more information, go to www.idri.org.
IDRI Contact: media@idri.org, 206-381-0883

About GSK
GlaxoSmithKline:  A Leader in Vaccines
GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline's vaccines business, is one of the world's leading vaccine companies and a leader in innovation.   The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing around the world and 20 more in development.

For more information, go to www.gsk.com.


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline CEO and CFO Interviewed on Q2 2011 Results
2. GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older
3. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
4. GlaxoSmithKline Confirms allis Safety Profile
5. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
6. GlaxoSmithKline Wins Environmental Stewardship Award
7. GlaxoSmithKline 15th Annual IMPACT Awards Seek Philadelphia Area and Camden Healthcare Nonprofits
8. GlaxoSmithKline Applauds North Carolinas Child Advocates
9. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
10. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
11. GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
Breaking Medicine News(10 mins):